HE resources
Salix Pharmaceuticals, Inc., is committed to providing support for adults living with overt hepatic encephalopathy (HE) and their caregivers.
Click below for more information and resources.
Caregiver support
Taking care of an adult living with overt HE can be difficult. It is important to follow any instructions given to you (or to the person you are caring for) by his or her doctor. These instructions may include:
Back to top
Savings information
Co-pay assistance is available (for eligible patients*) through the Hepatic Encephalopathy Living Program (H.E.L.P.). Patients ≥18 years of age living with overt HE can save up to $100 per month on their Xifaxan 550 mg prescriptions.
*The Xifaxan550 Savings Card is not available for residents of MA or patients whose prescription plan is paid/partially paid by Medicaid, Medicare, or federal or state government programs. VOID where prohibited by law.
Enroll in H.E.L.P. and receive a Xifaxan550 Savings Card
Enroll in H.E.L.P.
Already enrolled in H.E.L.P.?
Download or activate your Xifaxan550 Savings Card
Back to top
Reimbursement support
For all insurance-related questions, you can contact our reimbursement support service. Adults living with overt HE (or their caregivers) can call the Xifaxan 550 mg reimbursement hotline at 1-866-XIFAXAN (943-2926).
This free support service connects you with a trained reimbursement analyst who can answer any questions you may have. The office is open Monday–Friday, 8:30 am–5:30 pm EST.
Back to top
Track your HE symptoms
Use the HE Symptom Tracker to help you keep track of any HE signs or symptoms you might be experiencing, and bring it to your next doctor's appointment.
Download the HE Symptom Tracker
Back to top
IMPORTANT SAFETY INFORMATION
XIFAXAN 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥18 years of age. In the trials of XIFAXAN for HE, 91% of the patients were using lactulose concomitantly. XIFAXAN has not been studied in patients with MELD scores >25, and only 8.6% of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction. Therefore, caution should be exercised when administering XIFAXAN to patients with severe hepatic impairment (Child-Pugh C).
XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon which may lead to overgrowth of C. difficile. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
The most common adverse reactions occurring in >8% of patients in the clinical study were edema peripheral (15%), nausea (14%), dizziness (13%), fatigue (12%), ascites (11%), muscle spasms (9%), pruritus (9%), and abdominal pain (9%).
Xifaxan550 is not available for sale outside the U.S.
Xifaxan550 is licensed by Alfa Wassermann S.p.A. to Salix Pharmaceuticals, Inc.
Complete Prescribing Information.
You are encouraged to report negative side effects to the FDA. Visit www.fda.gov/safety/medwatch/ or call 1-800-FDA-1088.
For product information, adverse event reports, and product complaint reports, please contact:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
E-mail: Salix@medcomsol.com
Use of this site signifies your agreement to the . .
©2011 Salix Pharmaceuticals, Inc. All rights reserved. RIF 10/44-7
8510 Colonnade Center Drive, Raleigh NC 27615 U.S.A. T: 866-669-SLXP (7597), F: 919-862-1095